Tim Harkness, Unchained Labs CEO
The Carlyle Group shells out $435M for controlling stake in vaccine, gene therapy services company
The Carlyle Group has put a target on life sciences in recent years, looking for opportunities to take controlling stakes in promising firms. After shelling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.